Tandem Diabetes Care TNDM remained under pressure on Monday, after the company accounted for plans of a combined analysis of three trials of its Control-IQ technology. Tandem Diabetes Care’s margins ...
An artificial pancreas developed at the University of Virginia Center for Diabetes Technology improves blood sugar control for people ages 2 to 72 with type 1 diabetes, according to a new combined ...
Helping toddlers manage their Type 1 diabetes—typically a difficult task, due to their constant growth and development, not to mention fussiness—may now be a bit easier. The FDA has expanded its ...
Tandem Diabetes Care has already proven that its closed-loop system for automated insulin delivery can improve the amount of time spent in range for people of all ages with Type 1 diabetes, but a new ...
A new study evaluated the effect of hybrid-closed loop Control-IQ technology in the pooled data from three randomized controlled trials, comparing Control-IQ to a control group using continuous ...
NEW ORLEANS--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a global insulin delivery and diabetes technology company, announced positive real-world data demonstrating immediate and ...
Tandem Diabetes Care, Inc. TNDM presented positive real-world data, showing immediate and continued benefits across a diverse group of people using the t:slim X2 insulin pump with the Control-IQ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback